The History of Terrorism
Preview
Open in TheBrain
Links
Fascism AKA Corporatism
Organizational culture
Leadership
Governance
Corporate governance
Board of directors
Board of directors by company or organization
Board of Directors at The Scripps Research Institute
John C. Martin (businessman)
Attachments
John C. Martin (businessman)
Parents
1890-Today University of Chicago (U of C, Chicago, or UChicago)
1901-Today Golden Gate University (GGU)
1924-Today Scripps Research
1955-Today National Institute of Allergy and Infectious Diseases (NIAID)
1995-Today Presidential Advisory Council on HIV/AIDS (PACHA)
1999-Today Biotechnology Heritage Award
American billionaires
American chief executives in technology
Biotechnologists
Board of Directors at The Scripps Research Institute
Board of Directors of Scripps Research
Boards of Trustees of the University of Chicago
Businesspeople in the healthcare industry
Centers for Disease Control and Prevention/Health Resources and Services Administration's Advisory Committee on HIV and STD Prevention and Treatment
Chairmen of the Board of Gilead Sciences
Chairmen of the California Healthcare Institute
Directors of antiviral chemistry at Bristol-Myers Squibb
EY Entrepreneur of the Year Award
Gertrude B. Elion Award for Scientific Excellence
Golden Gate University Board of Trustees
Isbell Award
Lifetime Achievement Award for Public Service
National Academy of Engineering (NAE)
Presidents of the International Society for Antiviral Research
Purdue University
Syntex Corporation (Laboratorios Syntex SA)
Children
1987-Today Gilead Sciences (NASDAQ: GILD)
1990 Martin received the American Chemical Society's Isbell Award, "for his applications of carbohydrate chemistry to the design of medicinally active nucleosides and nucleotides."
2008 Martin became a member of the National Academy of Engineering, "for the invention, development, and commercialization of anti-viral medicines, especially treatments for HIV/AIDS."
2014 Martin is credited with taking Sovaldi from "zero-to-blockbuster in a couple of months" with profits topping $10 billion for 2014.
2015 Martin was named by investment firm Morningstar as best CEO.
Efavirenz/emtricitabine/tenofovir (Atripla)
Pre-exposure prophylaxis (PrEP)
Sofosbuvir (Sovaldi)